Pharma Mar, S.A. (0RC6) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you, Laura, and good morning to everyone. I'd like to welcome to all of you to our full 22 results conference call. On the call with me today are Mr. Luis Mora, Managing Director of Farmama, Maria Luisa de Francia, Chief Financial Officer, and Pascal Besman, which is Vice President, Strategic Development. Following our prepared remarks today, we'll open the line for questions. And before we start, I'd like to remind you that today's conference call may include forward-looking statements regarding future events or the future financial and operating performance of a company. Such forward-looking statements are only predictions based on our current expectations, and actual results may vary from those projected. We disclaim any obligation to update any information provided herein. And we refer you to our safe harbor statement and our corporate presentation, which is available on our website together with the press release and the report of the results we released yesterday. Last year, it was an important year for the company because we achieved important goals and we had an important advance in our development. I guess you had a chance to see our press release yesterday, so I'll not go through every little detail, but let me highlight the most important news from last year. In 22, we saw the approval of lorbinactidine for commercialization for the treatment of small cell lung cancer in countries like South Korea, Qatar, or Emirates. That adds, of course, to U.S., Australia, or Singapore, where the drug has been approved already. As you know, one of our main targets with Abcelka in the next future is to achieve approval in Europe and full approval in the U.S., And in the meantime, we'll have more news about approvals and filings in other countries. Talking about oth...